What will we discuss today?

Similar documents
Autoimmune diseases. SLIDE 3: Introduction to autoimmune diseases Chronic

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval

Disclosures. Rheumatological Approaches to Differential Diagnosis, Physical Examination, and Interpretation of Studies. None

Myositis and Your Lungs

NATIONAL LABORATORY HANDBOOK. Laboratory Testing for Antinuclear antibodies

Budsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital

Clinical Laboratory. [None

SCLERODERMA 101. Maureen D. Mayes, MD, MPH Professor of Medicine University of Texas - Houston

Clinical Laboratory. 14:41:00 Complement Component 3 50 mg/dl Oct-18

High Impact Rheumatology

Is it Autoimmune or NOT! Presented to AONP! October 2015!

The Power of the ANA. April 2018 Emily Littlejohn, DO MPH

Tools to Aid in the Accurate Diagnosis of. Connective Tissue Disease

Autoantibodies in the Idiopathic Inflammatory Myopathies

Autoantibodies panel ANA

Alida R Harahap & Farida Oesman Department of Clinical Pathology Faculty of Medicine, University of Indonesia

Citation The Journal of dermatology, 37(1), available at

Disclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease

Scleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Edward Dwyer, M.D. Division of Rheumatology

Scleroderma. Nomenclature Synonyms. Scleroderma. Progressive Systemic Sclerosis. Systemic Sclerosis. Limited vs. Diffuse Scleroderma.

Undifferentiated Connective Tissue Disease and Overlap Syndromes. Mark S. Box, MD

Clinical Laboratory. 14:42:00 SSA-52 (Ro52) (ENA) Antibody, IgG 1 AU/mL [0-40] Oct-18

Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation

Immune tolerance, autoimmune diseases

INTERPRETATION OF LABORATORY TESTS IN RHEUMATIC DISEASE

2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.

University of Pretoria

Assays. New. New. Combinations. Possibilities. Patents: EP , AU

Autoimmune (AI) Disorders

Autoimmunity. Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens

CTD-related Lung Disease

LUPUS. and Associated Conditions LUPUSUK 2015

Editing file. Color code: Important in red Extra in blue. Autoimmune Diseases

The Diagnosis of Lupus

LUPUS. and Associated Conditions LUPUSUK 2018

We also assessed the diagnostic significance of the SUBJECTS

Update in Systemic Sclerosis! Lauren Kim MD! NW Rheumatology Associates

INFLAMMATORY DISEASES PART I. Immunopathology Part I

What is Autoimmunity?

What is Autoimmunity?

DISCLOSURE. Relevant relationships with commercial entities none. Potential for conflicts of interest within this presentation none

Introduce the important components of the immune system Show how they interact & protect the body

Inflammatory Myopathies 4 th year MBBS. Marwan Adwan MBChB, MSc, MRCPI, MRCP(rheum) Consultant Rheumatologist

Lupus as a risk factor for cardiovascular disease

Detection of Anti-nuclear Antibodies in Women with Hyperprolactinaemia

Mechanisms of Autontibodies

Self-tolerance. Lack of immune responsiveness to an individual s own tissue antigens. Central Tolerance. Peripheral tolerance

New Therapeutic Perspectives in Sjögren's Syndrome

Pharmaceutical pathology

. Autoimmune disease. Dr. Baha,Hamdi.AL-Amiedi Ph.D.Microbiology

Essential Rheumatology. Dr Ellen Bruce Consultant Rheumatologist CMFT

Environmental Influence in Autoimmune Diseases. Mark Gourley, MD

Autoimmune diagnostics. A comprehensive product line for the detection of autoantibodies

How the Innate Immune System Profiles Pathogens

AMPLIADO SÍNDROME ANTIFOSFOLÍPIDO SÍNDROME DE SJÖGREN María José Cuadrado Lozano Clínica Universidad de Navarra-Madrid

.,Dr Ali Alkazzaz Babylon collage of medicine 2016

A glossary of medical terms

An Overview of Blood and Marrow Transplantation

Antibodies to nuclear antigens in polymyositis:

MOLECULAR IMMUNOLOGY Manipulation of immune response Autoimmune diseases & the pathogenic mechanism

RHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center

different serological and histological manifestations and a high incidence of D-penicillamine side effects. Materials

... CLINICIAN INTERVIEW... Managing Dry Eyes and Dry Mouth in Sjögren s Syndrome

Rheumatologic Lab Tests

Measurement of Antinuclear Antibodies: Assessment of Different Test Systems

This month, we are very pleased to introduce some new tests for Scleroderma as well as some test changes to our existing scleroderma tests/panels.

Policy. Section: Medicine Effective Date: January 15, 2015 Subsection: Pathology/Laboratory Original Policy Date: December 5, 2014 Subject:

Dr Ian Roberts Oxford

Immunology. Lecture- 8

MANAGING THE PATIENT WITH POSITIVE ANA

AUTOANTIBODIES PRECEDING AUTOIMMUNE DISEASES

ANTINUCLEAR ANTIBODIES IN LOCALIZED SCLERODERMA

SCLERODERMA: An Update. What You Need To Know

A clinical syndrome, composed mainly of:

Comments on the article by Tabache F. et al. Acute polyarthritis after influenza A H1N1 immunization,

Topic (Final-03): Immunologic Tolerance and Autoimmunity-Part II

Review. Undifferentiated connective tissue diseases (UCTD): A review of the literature and a proposal for preliminary classification criteria

Morning Report Presentation. Sarah Hughes, MD January 11, 2005

associated conditions a closer look at connective tissue disease and PAH

Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations

9/25/2013 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Rheumatologic Testing in Primary Care

Jeopardy. What s the rash? $100 $100 $100 $100 $100 $200 $200 $200 $200 $200 $300 $300 $300 $300 $300 $400 $400 $400 $400 $400

AUTOIMMUNE DISORDERS IN THE ACUTE SETTING

Understanding Autoimmune Diseases: Evolving Issues. Alvina D. Chu, M.D. April 23, 2009

PS + MPs PS - MPs 37% 36% 64% 64%

Investigation of novel autoantibodies in Sjogren s syndrome utilizing Sera from the Sjogren s international collaborative clinical alliance cohort

Undifferentiated connective tissue diseases in 2004

SLE-key Case Studies

The Immune System and Immune Mediated Diseases Dan Lodge-Rigal, M.D.

Preview of the Medifocus Guidebook on: Sjogren's Syndrome Updated January 5, 2019

Scleroderma Facts. The Scleroderma Foundation is here to help!

Cellular Pathology of immunological disorders

Systemic sclerosis (SSC)

SF-DCT INFORMATION FOR PRIMARY SJOGREN S SYNDROME (PSS) CLAIMS

Screening of Auto Antibodies using Indirect Immunofluorescence in Auto Immune Disease Patients

Connective tissue diseases, multimorbidity and the ageing lung

Transcription:

Autoimmune diseases

What will we discuss today? Introduction to autoimmune diseases Some examples

Introduction to autoimmune diseases Chronic Sometimes relapsing Progressive damage Epitope spreading more and more damage Actions may be by: -autoantibodies -Th1 & Th17 cells -CD8 cells -both cellular and humoral

Introduction, cont d Autoimmune diseases may be Systemic Organ-specific Tend to involve connective tissues blood vessels = collagen vascular diseases = connective tissue diseases We will discuss some of these

Examples Systemic lupus erythematosus (SLE) Sjogren syndrome Systemic sclerosis

SLE Autoantibodies/immune complexes Onset: acute or insidious Typically: chronic, remitting and relapsing Often febrile illness 20s & 30s F:M ratio: 9:1 in reproductive age Blacks & Hispanics more * Skin joints kidney serosal membranes any other organ

Important antibodies Robbins and Cotran pathologic basis of disease 9 th edition.. The table was compiled with the help of Dr. Antony Rosen, Johns Hopkins University

Investigations, indirect immunofluorescence homogenous speckled centromeric nucleolar Visit https://en.wikipedia.org/wiki/anti-nuclear_antibody for references

Investigations, cont d Antibodies to double-stranded DNA and the so-called Smith (Sm) antigen are virtually diagnostic of SLE In addition to ANAs, 30-40% of lupus patients also have autoantibodies against proteins complexed with phospholipids Its Ab also binds to cardiolipin antigen Plasma proteins: -prothrombin -annexin V -Beta 2-glycoprotein I -protein S -Protein C Lupus anticoagulant?

Risk factors Genetic susceptibility HLA-DQ polymorphisms inherited deficiencies of C2, C4, or C1q others Environmental factors are more important UV light and drugs Immunological factors: -Failure of self-tolerance in B cells -CD4+ helper T cells -Role of TLRs -Role of type I interferons -Role of BAFF

Mechanisms Systemic lesions mostly by type III hypersensitivity Opsonization of blood cells by autoantibodies Antiphospholipid antibody syndrome

Sjogren syndrome Most commonly in women between the ages of 50 and 60 Dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia) Primary or secondary Lymphocytic infiltration and fibrosis of lacrimal and salivary glands Mainly CD4+ and B cells 75% are positive for rheumatoid factor ANAs in 50-80%

Sjogren syndrome, cont d The most important antibodies are: SS-A & SS-B 90% HLA association -earlier onset -longer disease duration -extraglandular manifestations Viral infection may be the initial trigger

Sjogren syndrome, cont d Sjogren syndrome-like disease is seen in some patients with AIDS & hepatitis C Extraglandular disease in 1/3 of patients -synovitis -pulmonary fibrosis -neuropathy

Sjogren syndrome, cont d Biopsy of the lip Robbins and Cotran pathologic basis of disease 9 th edition.. Courtesy Dr. Dennis Burns, Department of Pathology, University of Texas Southwestern Medical School, Dallas, Texas

Systemic sclerosis (scleroderma) 50s-60s M:F 1:3 Its distinctive features are the striking cutaneous changes, notably skin thickening

Systemic sclerosis (scleroderma), cont d 3 main problems: -Inflammation CD4+ also humoral roles -Small blood vessel damage -Interstitial and perivascular fibrosis in skin and other tissues The majority: also kidney, heart, lung and GI involvement but late Diffuse VS limited scleroderma Some patients: CREST syndrome

Systemic sclerosis (scleroderma), cont d Raynaud phenomenon virtually in all patients precedes other manifestations in 70% of the cases Dysphagia is an important symptom 50% Nephrotic syndrome is rare The most dangerous risk: malignant hypertension

Two ANAs are important in diagnosing systemic sclerosis 1- against DNA topoisomerase I (anti-scl 70) highly specific 10-20% of diffuse disease prognostically important 2-anticentromere antibody 20-30% more with CREST syndrome